Home › Trial NCT01048320
Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer
- Trial IDNCT01048320
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorRoyal Marsden NHS Foundation Trust
- Enrollment36
- Start date2006-07
- ConditionsAdvanced Pancreatic Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.